An observational study in Gastroesophageal Reflux Disease (GERD), sponsored by Implantica CE Reflux Ltd.. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Implantica CE Reflux Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Gastroesophageal Reflux with a site in Italy — 12 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Italy.
Among the 78 studies in Gastroesophageal Reflux with a site in Italy, this one is the 4th largest by planned enrollment of the 30 observational ones that give a count, is one of 4 that started in 2023, is one of 30 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 62nd registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →12 of the 78 studies in Gastroesophageal Reflux with a site in Italy are open now. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Healthy volunteers
Devintec Sagl · Sites in Italy
Ages 18–75
United Pharmaceuticals · Sites in Italy, Belgium, France and 1 more country
Ages 2 wk–4 mo
Medtronic Cardiovascular · Sites in Italy, Denmark, France and 5 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 3 mo–24 mo
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 11 · Phase 4 5
First in 1995; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 180 across 349 observational studies indexed under Gastroesophageal Reflux.
Median enrollment 80 across the 48 interventional studies, 139 across the 30 observational. Of the 52 that completed or were terminated, 12 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 78 have an industry lead sponsor. The 10 most frequent:
Implantica CE Reflux Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Implantica CE Reflux Ltd. has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
4 of the studies in Gastroesophageal Reflux with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04358146United PharmaceuticalsStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR) | 2026-12-03 |
| NCT06984484Devintec SaglPerformance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease | 2027-01 |
| NCT07036627University of BariIntestinal Microbiota After PPI Treatment | 2027-01-01 |
| NCT07790549Liaquat University of Medical & Health SciencesMirgeal® Gel as Add-on Therapy to Esomeprazole in Adults With Non-Erosive Gastroesophageal Reflux Disease | 2027-01-29 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in Gastroesophageal Reflux with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
RefluxStop device and Nissen fundoplication are indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD) defined by abnormal pH testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: RefluxStop implantation
Procedure: Nissen fundoplication
Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
Standard of care Nissen fundoplication surgery
Primary safety endpoint
Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs)
Time frame: 6 months
Primary performance endpoint
Assessment of GERD symptoms, measured by GERD Health-Related Quality of Life (HRQL) score (questions 1-10). (An answer of zero means no symptoms)
Time frame: 6 months
Secondary safety endpoint
Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs) at 3 months and annually up to 5 years. Plus Incidence of Adverse Device Effects (ADEs) and procedure related or unknown Adverse Events (AEs) at 3 and 6 months and annually up to 5 years
Time frame: 3 and 6 months and annually up to 5 years
Secondary performance endpoints
Assessment of GERD symptoms, assessed by GERD-HRQL score (questions 1-10)
Time frame: 3 months and annually up to 5 years
Secondary performance endpoints: RefluxStop device position
Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device
Time frame: 6 months
Secondary performance endpoints: hernia assessment
Location of baseline hernia or any new hernia by a simplified contrast swallow x-ray picture
Time frame: 6 months
Secondary performance endpoints: pH monitoring
Reduction or normalisation from baseline of the total acid (pH\<4) exposure time during 24-hour pH monitoring
Time frame: 6 months
Exploratory endpoints: Patient Reported Outcomes - Quality of life questionnaire
EQ-5D (Euro Quality of life-5 Dimension) questionnaire: measure of quality of life with one question for each of the five dimensions that are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, the patients assess if they have no problem, slight, moderate, severe or extreme problems.
Time frame: 3 and 6 months and annually up to 5 years
Exploratory endpoints: Patient Reported Outcomes - Work related questionnaire
WPAI (work related productivity gains): 5 questions to assess how health problems effect the patient work Score 0 to 10. Zero meaning health problems have no effect on work
Time frame: 3 and 6 months and annually up to 5 years
Exploratory endpoints: Health economic outcomes - Visit to General Practitioner
Evaluation of number of visit to the General Practitioner
Time frame: 3 and 6 months and annually up to 5 years
Exploratory endpoints: Health economic outcomes - PPI treatment use
Counting of the number of patients using PPI (Proton Pump Inhibitors)
Time frame: 3 and 6 months and annually up to 5 years
Exploratory endpoints: Health economic outcomes - Re-admission to hospital
Counting of the number of re-admission to hospital due to complications
Time frame: 3 and 6 months and annually up to 5 years
Exploratory endpoints: Health economic outcomes - Procedure costs
Evaluation of the costs related to the study procedure and the length of hospital stay
Time frame: 3 and 6 months and annually up to 5 years
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 33 months after the start.
Of 117 observational studies under Gastroesophageal Reflux, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 134. This study's planned 33 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Implantica CE Reflux Ltd.